Scholar Rock Holding Corp: management transactions · United States · SEC (Form 4)

About Scholar Rock Holding Corp

Scholar Rock Holding Corp (NASDAQ: SRRK) is a U.S.-based biopharmaceutical company headquartered in Cambridge, Massachusetts, United States. Founded in October 2012, the company has built its strategy around discovering and developing medicines that selectively target disease biology in severe conditions with high unmet medical need, especially rare neuromuscular disorders. For French-, Belgian- and Swiss-based investors, Scholar Rock should be viewed as a development-stage biotech transitioning toward commercialization, with the usual sector characteristics: meaningful scientific upside, regulatory risk, and a valuation profile that can move sharply on clinical or CMC-related news. The company has been publicly traded on the NASDAQ Global Select Market since May 24, 2018, under the ticker SRRK. Scholar Rock’s lead program is apitegromab, a selective myostatin inhibitor being developed primarily for spinal muscular atrophy (SMA). The company has broadened the apitegromab franchise into additional neuromuscular indications, including facioscapulohumeral muscular dystrophy (FSHD), reflecting a platform approach rather than a single-indication asset. In parallel, Scholar Rock continues to advance a broader pipeline, including preclinical programs such as SRK-181 in fibrotic disease and other earlier-stage assets. Still, from an equity perspective, the story remains highly concentrated on the clinical, regulatory, and commercial trajectory of apitegromab. Competitive positioning is centered on the company’s selective biology and its focus on functional outcomes such as muscle strength and motor performance. In a field populated by specialty biotech peers and larger pharmaceutical companies, Scholar Rock’s differentiation depends on whether apitegromab can continue to demonstrate clinically meaningful benefit in SMA and potentially other muscle-wasting disorders. The company’s geographic footprint is currently anchored in the United States, but it has also prepared for European expansion, signaling an ambition to become a more global neuromuscular disease franchise if approvals are secured. Recent developments have been material. In 2025, Scholar Rock’s BLA for apitegromab was accepted for FDA review, but in September 2025 the company received a Complete Response Letter tied to manufacturing observations at the Catalent Indiana facility. In early 2026, Scholar Rock said it was working with regulators and had resubmitted the BLA, while continuing clinical development in SMA and FSHD. That regulatory and manufacturing sequence is central to the investment case: the stock is likely to be driven less by broad market trends than by FDA timing, execution on supply-chain readiness, and the progress of late-stage neuromuscular programs. As a result, SRRK remains a classic high-risk, high-upside U.S. biotech name on NASDAQ, best evaluated through a clinical/regulatory lens rather than traditional earnings multiples.